Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by equities researchers at Mizuho from a “buy” rating to a “neutral” rating in a research note issued to investors on Wednesday. They currently have a $16.00 price objective on the biotechnology company’s stock. Mizuho’s price target would suggest a potential upside of 1.27% from the company’s current price.

IRWD has been the subject of several other reports. BidaskClub raised Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. ValuEngine raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Credit Suisse Group started coverage on Ironwood Pharmaceuticals in a research note on Monday, November 27th. They set a “buy” rating and a $19.00 price objective for the company. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday. Finally, Cowen set a $20.00 price objective on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 21st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $17.88.

Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at $15.80 on Wednesday. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. Ironwood Pharmaceuticals has a one year low of $13.43 and a one year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. The firm had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The firm’s quarterly revenue was up 31.3% on a year-over-year basis. During the same period last year, the company posted ($0.18) EPS. research analysts predict that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio lifted its holdings in shares of Ironwood Pharmaceuticals by 4.8% in the third quarter. Public Employees Retirement System of Ohio now owns 120,888 shares of the biotechnology company’s stock valued at $1,906,000 after purchasing an additional 5,513 shares in the last quarter. California Public Employees Retirement System lifted its holdings in shares of Ironwood Pharmaceuticals by 7.1% in the third quarter. California Public Employees Retirement System now owns 246,617 shares of the biotechnology company’s stock valued at $3,889,000 after purchasing an additional 16,417 shares in the last quarter. Granahan Investment Management Inc. MA lifted its holdings in shares of Ironwood Pharmaceuticals by 24.5% in the third quarter. Granahan Investment Management Inc. MA now owns 436,000 shares of the biotechnology company’s stock valued at $6,876,000 after purchasing an additional 85,904 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 30.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 23,405 shares of the biotechnology company’s stock valued at $369,000 after purchasing an additional 5,527 shares in the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at $170,000.

TRADEMARK VIOLATION WARNING: “Ironwood Pharmaceuticals (IRWD) Lowered to Neutral at Mizuho” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/06/ironwood-pharmaceuticals-irwd-lowered-to-neutral-at-mizuho.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.